These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

986 related items for PubMed ID: 21393452

  • 1. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J.
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [Abstract] [Full Text] [Related]

  • 2. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A.
    Braz J Microbiol; 2015 Jul; 46(4):1125-33. PubMed ID: 26691471
    [Abstract] [Full Text] [Related]

  • 3. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 4. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH, Huang PY, Cheng CW, Shie SS, Lin ZF, Yang LY, Lee CH, Wu TS.
    Med Mycol; 2021 Nov 03; 59(11):1114-1121. PubMed ID: 34374784
    [Abstract] [Full Text] [Related]

  • 5. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK, Souza Junior AH, Costa CR, Faganello J, Vainstein MH, Chagas AL, Souza AC, Silva MR.
    Mycoses; 2010 Jan 03; 53(1):62-7. PubMed ID: 19500261
    [Abstract] [Full Text] [Related]

  • 6. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

  • 7. Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update.
    Chowdhary A, Rhandhawa HS, Prakash A, Meis JF.
    Crit Rev Microbiol; 2012 Feb 01; 38(1):1-16. PubMed ID: 22133016
    [Abstract] [Full Text] [Related]

  • 8. Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII.
    Aminnejad M, Diaz M, Arabatzis M, Castañeda E, Lazera M, Velegraki A, Marriott D, Sorrell TC, Meyer W.
    Mycopathologia; 2012 Jun 01; 173(5-6):337-46. PubMed ID: 22081254
    [Abstract] [Full Text] [Related]

  • 9. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E, Vitali LH, Kress MRVZ, Martinez R.
    Rev Inst Med Trop Sao Paulo; 2017 Jun 01; 59():e49. PubMed ID: 28793019
    [Abstract] [Full Text] [Related]

  • 10. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J.
    Antimicrob Agents Chemother; 2012 Nov 01; 56(11):5898-906. PubMed ID: 22948877
    [Abstract] [Full Text] [Related]

  • 11. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ, Wu HC, Hsueh PR.
    Clin Microbiol Infect; 2010 Jun 01; 16(6):696-703. PubMed ID: 19694765
    [Abstract] [Full Text] [Related]

  • 12. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM, Almeida-Paes R, Brito-Santos F, Nascimento CR, Fialho MM, Trilles L, Morales BP, da Silva SA, Santos W, Santos LO, Fortes ST, Cardarelli-Leite P, Lázera MDS.
    Med Mycol; 2019 Oct 01; 57(7):864-873. PubMed ID: 30657975
    [Abstract] [Full Text] [Related]

  • 13. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul 01; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 14. In vitro Antifungal Susceptibility Profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii Clinical Isolates in Guangxi, Southern China.
    Al-Odaini N, Li XY, Li BK, Chen XC, Huang CY, Lv CY, Pan KS, Zheng DY, Zheng YQ, Liao WQ, Cao CW.
    Front Microbiol; 2021 Jul 01; 12():708280. PubMed ID: 34447360
    [Abstract] [Full Text] [Related]

  • 15. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R, Fuchs V, Graf B, Hamprecht A, Hogardt M, Sedlacek L, Schwarz R, Idelevich EA, Becker SL, Held J, Küpper-Tetzel CP, McCormick-Smith I, Heckmann D, Gerkrath J, Han CO, Wilmes D, Rickerts V.
    Int J Med Microbiol; 2019 Sep 01; 309(6):151336. PubMed ID: 31444102
    [Abstract] [Full Text] [Related]

  • 16. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
    Zhang M, Zhou Z, Wang D, Zhou A, Song G, Chen X, Guo J, Wu W.
    Med Mycol; 2022 Mar 04; 60(3):. PubMed ID: 35099022
    [Abstract] [Full Text] [Related]

  • 17. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the Cryptococcus neoformans Complex in Jiangxi Province, South Central China.
    Yang C, Bian Z, Blechert O, Deng F, Chen H, Li Y, Yang Y, Chen M, Zhan P.
    Front Cell Infect Microbiol; 2021 Mar 04; 11():723251. PubMed ID: 34790585
    [Abstract] [Full Text] [Related]

  • 18. Cryptococcus neoformans/Cryptococcus gattii species complex in southern Italy: an overview on the environmental diffusion of serotypes, genotypes and mating-types.
    Romeo O, Scordino F, Chillemi V, Criseo G.
    Mycopathologia; 2012 Oct 04; 174(4):283-91. PubMed ID: 22531979
    [Abstract] [Full Text] [Related]

  • 19. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
    Bejar V, Tello M, García R, Guevara JM, Gonzales S, Vergaray G, Valencia E, Abanto E, Ortega-Loayza AG, Hagen F, Gutierrez EL.
    Rev Iberoam Micol; 2015 Oct 04; 32(2):88-92. PubMed ID: 25556051
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP, Trilles L, Bertho ÁL, Junior IN, de Oliveira Rde V, Wanke B, Lazéra Mdos S.
    Mycoses; 2015 May 04; 58(5):273-9. PubMed ID: 25756839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.